Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism

Volume: 25, Issue: 1, Pages: 15 - 24
Published: Jan 1, 2019
Abstract
The cost of treating all incarcerated people who have hepatitis C with direct-acting antiviral agents (DAAs) greatly stresses correctional facility budgets. Complex federal laws bar pharmaceutical companies from simply discounting expensive medications to prices that facilities can afford. This article discusses means by which correctional facilities may qualify under federal law as “safety-net providers” to allow sale of DAAs at a price <10% of...
Paper Details
Title
Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism
Published Date
Jan 1, 2019
Volume
25
Issue
1
Pages
15 - 24
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.